68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Nov 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 68Ga-JH12, which is designed to help doctors see certain types of cancer better by targeting a specific protein found in many tumors. The researchers want to learn about how safe this agent is, how it spreads in the body, and how much radiation it gives off. This study is open to adults aged 65 to 74 and 29 to 219 years old who have been diagnosed with various solid tumors, provided they have signed a consent form to participate. However, women who are pregnant or breastfeeding, as well as those with severe liver or kidney issues, cannot take part in the trial.

Participants in this study can expect to undergo imaging tests using the 68Ga-JH12 agent, which may help in understanding their cancer better and potentially lead to improved treatment options in the future. The trial is currently recruiting, so there is an opportunity for eligible patients to contribute to important research that could benefit others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Various solid tumors with available histopathological findings
• • Signed informed consent
• Exclusion Criteria:
• • pregnant or lactational women
• • who suffered from severe hepatic and renal insufficiency